ダメシェク
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2016/07/02 07:59:22」(JST)
[Wiki en表示]
Dameshek is a surname. Notable people with the surname include:
- Dave Dameshek (born 1970), American television writer
- William Dameshek (1900–1969), American hematologist
English Journal
- Jak-2 Positive Myeloproliferative Neoplasms.
- Muxí PJ1, Oliver AC.Author information 1Department of Haematology, British Hospital, Av. Italia 2420, Montevideo, Uruguay, muximeth@adinet.com.uy.AbstractOPINION STATEMENT: Originally described by Dameshek in 1951, myeloproliferative disorders are today classified as myeloproliferative Neoplasms (MPNs) in WHO's Classification of Tumors of Hematopoietic and Lymphoid Tissues. The term includes a range of conditions, [ie, BCR-ABL-positive chronic myelogenous leukemia (CML), chronic neutrophilic leukemia (CNL), polycythemia vera (PV), primary myelofibrosis (PMF), essential thromobocythemia (ET), chronic eosinophilic leukemia not otherwise specified (CEL-NOS), mastocytosis, and unclassifiable myeloproliferative neoplasm]. In the specific case of CML, a better understanding of the pathogenesis and pathophysiology of the disease has led to a targeted therapy. The presence of chromosome Philadelphia, t(9;22)(q34;11) results in the oncogene BCR-ABL, which characterizes the disease; this molecular rearrangement gives rise to a tyrosine-kinase, which in turn triggers the proliferation of the myeloid line through the activation of the signaling pathways downstream. Tyrosine-kinase inhibitors (TKIs) have altered the therapy and monitoring of CML patients and improved both their prognosis and quality of life. In 2005, various groups of investigators described a new point mutation of the gene JAK2 associated to MPNs. Although the presence of this mutation has led to a modification in the diagnostic criteria of these conditions, the impact of the use of JAK2 inhibitors on the prognosis and course of the disease continues to be controversial.
- Current treatment options in oncology.Curr Treat Options Oncol.2014 Mar 14. [Epub ahead of print]
- OPINION STATEMENT: Originally described by Dameshek in 1951, myeloproliferative disorders are today classified as myeloproliferative Neoplasms (MPNs) in WHO's Classification of Tumors of Hematopoietic and Lymphoid Tissues. The term includes a range of conditions, [ie, BCR-ABL-positive chronic myelog
- PMID 24627006
- Molecular classification of myeloproliferative neoplasms-pros and cons.
- Qureshi M1, Harrison C.Author information 1Department of Haematology, University College London Hospitals NHS Foundation Trust, University College London Hospital, 250 Euston Road, London, NW1 2PG, UK.AbstractDameshek first postulated a common myeloproliferative heritage for the myeloproliferative disorders, now termed neoplasms. This prescient observation was validated by the description of a common mutation in exon 14 of JAK2 for patients with essential thrombocythemia, polycythemia vera and primary myelofibrosis. In recent years, our knowledge of the molecular abnormalities underpinning these disorders has expanded significantly. At the same time, we have continued to use a classification based largely upon the first clinical descriptions of these entities, which sometimes proves problematic in differentiating between these conditions and normal reactive processes, myelodysplasia and between the myeloproliferative neoplasm entities themselves. Here, we discuss the pros and cons of a molecular classification and its potential utility in diagnosis, prognosis, and therapeutics.
- Current hematologic malignancy reports.Curr Hematol Malig Rep.2013 Dec;8(4):342-50. doi: 10.1007/s11899-013-0179-9.
- Dameshek first postulated a common myeloproliferative heritage for the myeloproliferative disorders, now termed neoplasms. This prescient observation was validated by the description of a common mutation in exon 14 of JAK2 for patients with essential thrombocythemia, polycythemia vera and primary my
- PMID 24091831
- Physiopathology, Etiologic Factors, Diagnosis, and Course of Polycythemia Vera as Related to Therapy According to William Dameshek, 1940-1950.
- Michiels JJ, Institute And Foundation G, Education Thrombocythemia Vera Study Group FO, Ewg Mpn TA.Abstractin
English, TurkishDameshek’e göre gerçek polistemi (polistemia vera: PV) eş zamanlı eritrositoz, lökositoz ve trombositozun olduğu, yayılma özelliği göstermeyen, tüm kemik iliğini ilgilendiren miyeloproliferatif bir hastalıktır. Olası kalıtsal veya iletilebilme eğilimi olabilir, ancak gerçek ailevi polistemi nadirdir. Etyolojiye yönelik olarak Dameshek 1950’de iki çok tartışmalı olasılık ileri sürmüştür: bilinmeyen faktör veya faktörlerce kemik iliğinin aşırı uyarılması ve normal baskılayıcı faktör veya faktörlerin eksikliği veya olmaması. Dameshek’in hipotezi 2005 yılında Fransa’da Vainchecker tarafından 3 klasik miyeloproliferatif neoplazinin fenotipinin nedeni olarak edinsel JAK2V617F mutasyonunun keşfi ile ispatlandı: esansiyel trombositemi, PV ve miyelofibroz. JAK2V617F mutasyonu Janus kinaz 2 (JAK2)’nin parçası JH1 kinaz üzerinde yer alan JH2 yalancı kinazın baskılayıcı aktivitesinin kaybına neden olmaktadır. Bu durum JAK2’nin normal JH1 kinaz aktivitesinin artışına neden olarak mutasyona uğramış hematopoetik kök hücrelerini trombopoetin, eritropoetin, insulin-benzeri büyüme faktörü-1, kök hücre faktörü ve granülosit koloni uyarıcı faktor gibi hematopoetik büyüme faktörlerine karşı ileri derecede hassaslaştırmak suretiyle her üç seride miyeloproliferasyona neden olmaktadır. Sonuç olarak, Dameshek tarafından gözlemlenen durum PV’da kemik iliğinde kan üretiminini sınırlayan tüm kontrol basamaklarının JAK2V617F mutasyonu ile ortadan kaldırıldığıdır.Dameshek PV hastalarını özünde normal olarak değerlendirdiğinden tedavinin mümkün olduğunca fizyolojik olması gerekmekteydi. Bu nedenle, sistematik flebotomi/demir eksikliği tedavi metodu önerildi; radyoaktif fosfor kullanımı dirençli ve major trombozu olan hastalara saklandı. Hasta yeterince uzun yaşar ve tromboz etkisi ya da diğer komplikasyonlara bağlı kaybedilmezse, ilik giderek azalan aktivite belirtileri gösterecektir. Kan yaymasında çekirdekli eritrositler, artmış polikromatofili, değişik tiplerde olgunlaşmamış granülositler izlenir. Eritropoetik dokunun gittikçe azalmasıyla, miyelofibroz daha çok organize bir fibröz doku kitlesine dönüşür. Aşırı büyüyen ve bazı olgularda tüm karın boşluğunu dolduran dalakta belirgin ekstramedüller hematopoez vardır. Büyümüş dalak, büyük ölçüde dalağın primer miyeloid metaplazisi alanında yerleşen metastatik kemik iliğinden meydana gelir.
- Turkish journal of haematology : official journal of Turkish Society of Haematology.Turk J Haematol.2013 Jun;30(2):102-110. Epub 2013 Jun 5.
- in
English, TurkishDameshek’e göre gerçek polistemi (polistemia vera: PV) eş zamanlı eritrositoz, lökositoz ve trombositozun olduğu, yayılma özelliği göstermeyen, tüm kemik iliğini ilgilendiren miyeloproliferatif bir hastalıktır. Olası kalıtsal veya iletilebilme eğilimi olabil
Japanese Journal
- The problem of clonality in aplastic anemia : Dr Dameshek's riddle, restated
- The problem of clonality in aplastic anemia: Dr Dameshek's riddle, restarted
- The problem of clonality in aplastic anemia. Dr. Dameshek's riddle, restated.
Related Links
- The latest Tweets from Dave Dameshek (@Dameshek). Accountant for Taste. WATCH on YouTube: https://t.co/FA0G0tJ7Wv LISTEN on https://t.co/4SoO94a2RC. Los Angeles ... Add a location to your Tweets When you tweet with ...
- Watch Shek and Bucky’s chat with Denzel Perryman HERE DDFP 349 http://traffic.libsyn.com/dameshek/DDFP_349_1-2-AIFF_to_MP3_80kbps.mp3 Shek is joined by Bucky Brooks and Matt “Money” Smith to discuss the NBA ...
Related Pictures
★リンクテーブル★
[★]
- 英
- Estren-Dameshek syndrome
- 同
- Estren-Dameshek症候群
[show details]
[★]
エストレン・ダメシェク症候群
[★]
エストレン・ダメシェク症候群
[★]
スペート・ダメシェク症候群